AI
Wednesday, April 01, 2015 6:31:41 AM
PharmaCyte Biotech Inc. >>> Insulin / Type 1 Diabetics / Cell-in-a-box >>>
Genetics breakthrough is a game changer for type 1 diabetes research
March 29, 2015
The genes that increase the risk of Type 1 diabetes have lost their hiding place.
A research group that includes a University of Florida genetics expert has located and narrowed down the number of genes that play a role in the disease, according to a study published Monday in the journal Nature Genetics. Knowing the identities and location of causative genes is a crucial development: Other researchers can use this information to better predict who might develop Type 1 diabetes and how to prevent it.
“It’s a game-changer for Type 1 diabetes,” said Patrick Concannon, director of the University of Florida Genetics Institute.
Diabetes mellitus type 1 (also known as type 1 diabetes, or T1DM; formerly insulin-dependent diabetes or juvenile diabetes) is a form of diabetes mellitus that results from the autoimmune destruction of the insulin-producing beta cells in the pancreas. The subsequent lack of insulin leads to increased blood and urine glucose. The classical symptoms are polyuria (frequent urination), polydipsia (increased thirst), polyphagia (increased hunger) and weight loss.
Diabetes mellitus type 1 accounts for between 5% and 10% of cases of diabetes. Globally, the number of people with DM type 1 is unknown, although it is estimated that about 80,000 children develop the disease each year. Within the United States the number of affected persons is estimated at one to three million. The development of new cases vary by country and region; the lowest rates appears to be in Japan and China with approximately 1 person per 100,000 per year; the highest rates are found in Scandinavia where it is closer to 35 new cases per 100,000 per year. The United States and northern Europe fall somewhere in between with 8-17 new cases per 100,000 per year.
Type 1 diabetes is estimated to cause $10.5 billion in annual medical costs ($875 per month per diabetic) and an additional $4.4 billion in indirect costs ($366 per month per person with diabetes) in the U.S
Researchers gathered information about the genetic makeup of 27,000 people, including those who had Type 1 diabetes and others who did not. They then began looking for individual differences in DNA that raise the risk of Type 1 diabetes. Starting with 200,000 possible locations in the genome, researchers used a technique known as fine mapping to pinpoint DNA sequence variations that can lead to diabetes. In some genomic regions, they narrowed the number of disease-causing DNA variations -- known as single nucleotide polymorphisms or SNPs -- from the thousands down to five or less.
That will make diabetes researchers’ work more effective and efficient by giving them the most detailed directions yet about where to look for the genetic variations that cause Type 1 diabetes and perhaps other autoimmune diseases such as arthritis, Concannon said. Now that the group of geneticists has identified the important genes and SNPs, diabetes researchers will reap the benefits, according to Concannon.
“We’ve taken this genetic data which was interesting but hard to work with, and we’ve condensed it down into something that people can actually use to begin to explore the mechanism of the disease. It moves it out of the realm of genetics to being broadly applicable to Type 1 diabetes research,” he said.
Type 1 diabetes occurs when the body’s immune system kills off insulin-producing cells in the pancreas. Some 3 million people in the United States have the disease, according to the JDRF, a group that funds Type 1 diabetes research and education. Experts don’t know exactly what causes the disease but suspect that genetics and environmental factors may play a role.
The researchers’ findings are the most comprehensive yet in the effort to locate and identify the genetic risk variants for Type 1 diabetes and other autoimmune diseases, said Todd Brusko, a member of the UF Diabetes Institute and an assistant professor in the UF College of Medicine’s department of pathology, immunology and laboratory medicine, part of UF Health.
Researchers can now shift away from trying to determine which genes heighten the risk for diseases like Type 1 diabetes, Brusko said. Instead, researchers can focus on how genetic changes alter immune cell activity. That, he said, could eventually lead to new treatments that prevent or stop Type 1 diabetes and other automimmune diseases.
“Ultimately, this information will allow researchers and clinicians to tailor treatments to correct underlying defects in the immune system that allow for autoimmune disease development,” Brusko said.
The findings are significant because certain interactions within the genome can now be analyzed to identify which genes and regulatory sequences cause the disease, said Stephen S. Rich, the study’s lead author and the director of the Center for Public Health Genomics at the University of Virginia. Defining the variants that cause Type 1 diabetes may lead to new therapeutic targets and treatments, he said.
http://nextbigfuture.com/2015/03/genetics-breakthrough-is-game-changer.html
Synthesized Cells that produce natural insulin more effective and efficient in Fighting Type 1 Diabetes
March 29, 2015
Patients with type 1 diabetes wont have to depend on insulin injections with what the team of Australian researchers have uncovered . The team have come up with a new and better way to counter problems with type 1 diabetic patients by synthesizing cells that produce the hormone insulin . The first artificial pancreas that will soon be introduced to the world will be using the cells . The US biotechnology company PharmaCyte Biotech had given their permission for the team to obtain the license .
In type 1 diabetes , an autoimmune disease , patients have problems with their blood glucose regulation since the islet cells of their pancreas are attacked by their immune system .
The new cells that are created are called the Melligen cells which were taken from the human liver cells. The liver and the pancreas are as studied to be composed from the same primordial cells which is what they use to genetically modify and make it work as the insulin-producing cells which is the islet cells.
The outcome was the display of the GM Melligen cells releasing insulin as a response of glucose in the surroundings . The researchers were pleased with the results which showed their findings had been very successful that they finally announced that they could help patients with type 1 diabetics to lessen their dependency on their daily insulin injections providing them with the most natural way of having their blood sugar regulated with the cells
The Melligen cells are to be contained in thte Cell-in-a-box capsule. It’s size is just about the same as a pin head which will be a cellulose- based capsule that holds cells within then fuses them into the human body.
The next step that researchers are going to work on will require the artificial transplant of the pancreas into animals . Eventually, the challenge of testing it on humans will be made possible and successful as well.
http://www.esbtrib.com/2015/03/29/8505/cells-that-produce-insulin-substitutes-insulin-injection/
Cells Producing Insulin By Themselves To Replace Injections
March 27 2015
Insulin injections might soon be a thing of the past; at least, for Type 1 diabetes patients. A team of Australian researchers have synthesised cells that produce the hormone insulin which could be the answer to that form of diabetes. The cells might soon be used in the world’s first artificial pancreas. The license was granted by the US biotechnology company PharmaCyte Biotech last October.
Type 1 diabetes is an autoimmune disease whereby the patient’s islet cells of the pancreas are attacked by his immune system such that the regulation of blood glucose becomes problematic.
The new cells that have been formed are called Melligen cells and they were derived from human liver cells; the liver and the pancreas are known to be forming from the same primordial cells, and, therefore, the liver cells were easily genetically modified to function as the insulin-producing cells, the islet cells.
Results showed that the GM Melligen cells released insulin as a response to the level of glucose found in their surroundings. The findings were so fruitful that the researchers concluded that they could help type 1 diabetes patients to decrease their dependency on daily injections; their blood sugar concentrations could be tuned naturally via these cells.
The Melligen cells will now have to be incorporated into the Cell-in-a-box® capsule. The latter which is about the same size as a pin head is a cellulose-based capsule that houses cells and later integrates them into the human body.
Another future step of the researchers will entail the transplantation of the artificial pancreases into animals. Thereafter, testing on humans will hopefully be possible.
http://news.islandcrisis.net/2015/03/cells-producing-insulin-by-themselves-to-replace-injections/
Type 1 Diabetics Will Soon Have Artificial Pancreases That Will Produce Insulin, Completely Eliminating The Need For Daily Injections
March 27, 2015
Insulin producing cells, created in a laboratory, will soon eliminate daily injections for type 1 diabetics.
Australian scientists have succeeded in creating cells that produce insulin on their own. These cells can potentially make daily insulin injections redundant. Scientists from the University of Technology, Sydney (UTS) managed to create these cells from regular liver cells, and they are already gearing up to incorporate them to a world-first bio-artificial pancreas after being licensed by U.S. biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has an innovative delivery mechanism, called the Cell-in-a-Box system, which is basically a tiny cellulose-based “capsule” that can house artificial cells and integrate them into a human body. This platform is quite revolutionary in the sense that it can be tweaked to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to. After acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sights on Type 1 diabetes.
Type 1 diabetes is essentially an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents them from properly regulating the body’s blood glucose levels, which is done by the timely release of insulin in controlled quantities.
Explaining why the new cell line, called as “Melligen” cells, is derived from healthy liver cells, instead of pancreatic cells, Ann Simpson from UTS: Science, who has been developing the cells over the past 20 years, offered the following explanation.
“When a fetus develops, the liver and the pancreas form from the same endodermal origin. This means that they should have the potential to do the same things as one another.”
Accordingly, healthy human liver cells have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells. So far, lab trials have been very promising, with these tweaked cells being able to release insulin in direct response to the amount of glucose in their surroundings. In a person suffering from type 1 diabetes, this work has to be done by painful injections.
The team plans to transplant artificial pancreases into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Diabetes is one of the most common diseases of the modern world, and the epidemic is growing alarmingly. Fortunately, scientists are busy devising innovative and non-invasive ways to treat diabetes and help people lead a normal live.
http://www.inquisitr.com/1960140/type-1-diabetics-will-soon-have-artificial-pancreases-that-will-produce-insulin-completely-eliminating-the-need-for-daily-injections/
Pharmacyte Biotech Inc (OTCMKTS:PMCB) Gaines Analysts Attention
March 27, 2015
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is on a run after it gained appreciation from two small-cap research companies. The stock jumped up by nearly 29% to $0.147 during the yesterday trade, where an average volume of 1.81 million shares changed hands. Firstly, the company received coverage from TickerResearch, which said that the company’s Cell-in-a-Box technology has a great potential to a breakthrough in the treatment of pancreatic cancer.
Cell-in-a-box
The research firm said that Pharmacyte Biotech Inc (OTCMKTS:PMCB) holds exclusive rights to develop therapies to treat solid cancerous tumors through its Cell-in-a-box technology in combination with drug ifosfamide in low combinations. The firm added that Pharmacyte Biotech Inc (OTCMKTS:PMCB) already has earned Orphan Drug Status for its technology that puts it ahead in the race of developing treatment for advanced pancreatic cancer.
The company is expected to clinical trials to test the efficacy and effectiveness of its solution against industry standard treatment, Gemcitabine. If the company can report positive results from trial, then it will be its turning point. The research firm stated that Pharmacyte Biotech Inc (OTCMKTS:PMCB) could be the next biotech winner in the market.
More hidden potential
Similarly, another research firm, Goldman Small Cap Research too take a positive view on the stock. The firm’s analyst Rob Goldman said that the company is positioned attractively, where it has a caliber to develop a therapy for the treatment of multiple forms of diabetes and cancer. The research firm reiterated that the Orphan Drug status will boost the company’s development efforts and could make it as a chief player in the treatment of pancreatic cancer.
The firm suggested that the potential of the company has been overlooked, and there is a lot more value in the stock than estimated. The firm also highlighted the possibility that the company’s technology has the chances to cure a number of diseases including diabetes and other forms of cancer.
http://www.journaltranscript.com/2015/03/pharmacyte-biotech-inc-otcmktspmcb-gaines-analysts-attention/
Genetics breakthrough is a game changer for type 1 diabetes research
March 29, 2015
The genes that increase the risk of Type 1 diabetes have lost their hiding place.
A research group that includes a University of Florida genetics expert has located and narrowed down the number of genes that play a role in the disease, according to a study published Monday in the journal Nature Genetics. Knowing the identities and location of causative genes is a crucial development: Other researchers can use this information to better predict who might develop Type 1 diabetes and how to prevent it.
“It’s a game-changer for Type 1 diabetes,” said Patrick Concannon, director of the University of Florida Genetics Institute.
Diabetes mellitus type 1 (also known as type 1 diabetes, or T1DM; formerly insulin-dependent diabetes or juvenile diabetes) is a form of diabetes mellitus that results from the autoimmune destruction of the insulin-producing beta cells in the pancreas. The subsequent lack of insulin leads to increased blood and urine glucose. The classical symptoms are polyuria (frequent urination), polydipsia (increased thirst), polyphagia (increased hunger) and weight loss.
Diabetes mellitus type 1 accounts for between 5% and 10% of cases of diabetes. Globally, the number of people with DM type 1 is unknown, although it is estimated that about 80,000 children develop the disease each year. Within the United States the number of affected persons is estimated at one to three million. The development of new cases vary by country and region; the lowest rates appears to be in Japan and China with approximately 1 person per 100,000 per year; the highest rates are found in Scandinavia where it is closer to 35 new cases per 100,000 per year. The United States and northern Europe fall somewhere in between with 8-17 new cases per 100,000 per year.
Type 1 diabetes is estimated to cause $10.5 billion in annual medical costs ($875 per month per diabetic) and an additional $4.4 billion in indirect costs ($366 per month per person with diabetes) in the U.S
Researchers gathered information about the genetic makeup of 27,000 people, including those who had Type 1 diabetes and others who did not. They then began looking for individual differences in DNA that raise the risk of Type 1 diabetes. Starting with 200,000 possible locations in the genome, researchers used a technique known as fine mapping to pinpoint DNA sequence variations that can lead to diabetes. In some genomic regions, they narrowed the number of disease-causing DNA variations -- known as single nucleotide polymorphisms or SNPs -- from the thousands down to five or less.
That will make diabetes researchers’ work more effective and efficient by giving them the most detailed directions yet about where to look for the genetic variations that cause Type 1 diabetes and perhaps other autoimmune diseases such as arthritis, Concannon said. Now that the group of geneticists has identified the important genes and SNPs, diabetes researchers will reap the benefits, according to Concannon.
“We’ve taken this genetic data which was interesting but hard to work with, and we’ve condensed it down into something that people can actually use to begin to explore the mechanism of the disease. It moves it out of the realm of genetics to being broadly applicable to Type 1 diabetes research,” he said.
Type 1 diabetes occurs when the body’s immune system kills off insulin-producing cells in the pancreas. Some 3 million people in the United States have the disease, according to the JDRF, a group that funds Type 1 diabetes research and education. Experts don’t know exactly what causes the disease but suspect that genetics and environmental factors may play a role.
The researchers’ findings are the most comprehensive yet in the effort to locate and identify the genetic risk variants for Type 1 diabetes and other autoimmune diseases, said Todd Brusko, a member of the UF Diabetes Institute and an assistant professor in the UF College of Medicine’s department of pathology, immunology and laboratory medicine, part of UF Health.
Researchers can now shift away from trying to determine which genes heighten the risk for diseases like Type 1 diabetes, Brusko said. Instead, researchers can focus on how genetic changes alter immune cell activity. That, he said, could eventually lead to new treatments that prevent or stop Type 1 diabetes and other automimmune diseases.
“Ultimately, this information will allow researchers and clinicians to tailor treatments to correct underlying defects in the immune system that allow for autoimmune disease development,” Brusko said.
The findings are significant because certain interactions within the genome can now be analyzed to identify which genes and regulatory sequences cause the disease, said Stephen S. Rich, the study’s lead author and the director of the Center for Public Health Genomics at the University of Virginia. Defining the variants that cause Type 1 diabetes may lead to new therapeutic targets and treatments, he said.
http://nextbigfuture.com/2015/03/genetics-breakthrough-is-game-changer.html
Synthesized Cells that produce natural insulin more effective and efficient in Fighting Type 1 Diabetes
March 29, 2015
Patients with type 1 diabetes wont have to depend on insulin injections with what the team of Australian researchers have uncovered . The team have come up with a new and better way to counter problems with type 1 diabetic patients by synthesizing cells that produce the hormone insulin . The first artificial pancreas that will soon be introduced to the world will be using the cells . The US biotechnology company PharmaCyte Biotech had given their permission for the team to obtain the license .
In type 1 diabetes , an autoimmune disease , patients have problems with their blood glucose regulation since the islet cells of their pancreas are attacked by their immune system .
The new cells that are created are called the Melligen cells which were taken from the human liver cells. The liver and the pancreas are as studied to be composed from the same primordial cells which is what they use to genetically modify and make it work as the insulin-producing cells which is the islet cells.
The outcome was the display of the GM Melligen cells releasing insulin as a response of glucose in the surroundings . The researchers were pleased with the results which showed their findings had been very successful that they finally announced that they could help patients with type 1 diabetics to lessen their dependency on their daily insulin injections providing them with the most natural way of having their blood sugar regulated with the cells
The Melligen cells are to be contained in thte Cell-in-a-box capsule. It’s size is just about the same as a pin head which will be a cellulose- based capsule that holds cells within then fuses them into the human body.
The next step that researchers are going to work on will require the artificial transplant of the pancreas into animals . Eventually, the challenge of testing it on humans will be made possible and successful as well.
http://www.esbtrib.com/2015/03/29/8505/cells-that-produce-insulin-substitutes-insulin-injection/
Cells Producing Insulin By Themselves To Replace Injections
March 27 2015
Insulin injections might soon be a thing of the past; at least, for Type 1 diabetes patients. A team of Australian researchers have synthesised cells that produce the hormone insulin which could be the answer to that form of diabetes. The cells might soon be used in the world’s first artificial pancreas. The license was granted by the US biotechnology company PharmaCyte Biotech last October.
Type 1 diabetes is an autoimmune disease whereby the patient’s islet cells of the pancreas are attacked by his immune system such that the regulation of blood glucose becomes problematic.
The new cells that have been formed are called Melligen cells and they were derived from human liver cells; the liver and the pancreas are known to be forming from the same primordial cells, and, therefore, the liver cells were easily genetically modified to function as the insulin-producing cells, the islet cells.
Results showed that the GM Melligen cells released insulin as a response to the level of glucose found in their surroundings. The findings were so fruitful that the researchers concluded that they could help type 1 diabetes patients to decrease their dependency on daily injections; their blood sugar concentrations could be tuned naturally via these cells.
The Melligen cells will now have to be incorporated into the Cell-in-a-box® capsule. The latter which is about the same size as a pin head is a cellulose-based capsule that houses cells and later integrates them into the human body.
Another future step of the researchers will entail the transplantation of the artificial pancreases into animals. Thereafter, testing on humans will hopefully be possible.
http://news.islandcrisis.net/2015/03/cells-producing-insulin-by-themselves-to-replace-injections/
Type 1 Diabetics Will Soon Have Artificial Pancreases That Will Produce Insulin, Completely Eliminating The Need For Daily Injections
March 27, 2015
Insulin producing cells, created in a laboratory, will soon eliminate daily injections for type 1 diabetics.
Australian scientists have succeeded in creating cells that produce insulin on their own. These cells can potentially make daily insulin injections redundant. Scientists from the University of Technology, Sydney (UTS) managed to create these cells from regular liver cells, and they are already gearing up to incorporate them to a world-first bio-artificial pancreas after being licensed by U.S. biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has an innovative delivery mechanism, called the Cell-in-a-Box system, which is basically a tiny cellulose-based “capsule” that can house artificial cells and integrate them into a human body. This platform is quite revolutionary in the sense that it can be tweaked to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to. After acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sights on Type 1 diabetes.
Type 1 diabetes is essentially an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents them from properly regulating the body’s blood glucose levels, which is done by the timely release of insulin in controlled quantities.
Explaining why the new cell line, called as “Melligen” cells, is derived from healthy liver cells, instead of pancreatic cells, Ann Simpson from UTS: Science, who has been developing the cells over the past 20 years, offered the following explanation.
“When a fetus develops, the liver and the pancreas form from the same endodermal origin. This means that they should have the potential to do the same things as one another.”
Accordingly, healthy human liver cells have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells. So far, lab trials have been very promising, with these tweaked cells being able to release insulin in direct response to the amount of glucose in their surroundings. In a person suffering from type 1 diabetes, this work has to be done by painful injections.
The team plans to transplant artificial pancreases into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Diabetes is one of the most common diseases of the modern world, and the epidemic is growing alarmingly. Fortunately, scientists are busy devising innovative and non-invasive ways to treat diabetes and help people lead a normal live.
http://www.inquisitr.com/1960140/type-1-diabetics-will-soon-have-artificial-pancreases-that-will-produce-insulin-completely-eliminating-the-need-for-daily-injections/
Pharmacyte Biotech Inc (OTCMKTS:PMCB) Gaines Analysts Attention
March 27, 2015
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is on a run after it gained appreciation from two small-cap research companies. The stock jumped up by nearly 29% to $0.147 during the yesterday trade, where an average volume of 1.81 million shares changed hands. Firstly, the company received coverage from TickerResearch, which said that the company’s Cell-in-a-Box technology has a great potential to a breakthrough in the treatment of pancreatic cancer.
Cell-in-a-box
The research firm said that Pharmacyte Biotech Inc (OTCMKTS:PMCB) holds exclusive rights to develop therapies to treat solid cancerous tumors through its Cell-in-a-box technology in combination with drug ifosfamide in low combinations. The firm added that Pharmacyte Biotech Inc (OTCMKTS:PMCB) already has earned Orphan Drug Status for its technology that puts it ahead in the race of developing treatment for advanced pancreatic cancer.
The company is expected to clinical trials to test the efficacy and effectiveness of its solution against industry standard treatment, Gemcitabine. If the company can report positive results from trial, then it will be its turning point. The research firm stated that Pharmacyte Biotech Inc (OTCMKTS:PMCB) could be the next biotech winner in the market.
More hidden potential
Similarly, another research firm, Goldman Small Cap Research too take a positive view on the stock. The firm’s analyst Rob Goldman said that the company is positioned attractively, where it has a caliber to develop a therapy for the treatment of multiple forms of diabetes and cancer. The research firm reiterated that the Orphan Drug status will boost the company’s development efforts and could make it as a chief player in the treatment of pancreatic cancer.
The firm suggested that the potential of the company has been overlooked, and there is a lot more value in the stock than estimated. The firm also highlighted the possibility that the company’s technology has the chances to cure a number of diseases including diabetes and other forms of cancer.
http://www.journaltranscript.com/2015/03/pharmacyte-biotech-inc-otcmktspmcb-gaines-analysts-attention/
Recent PMCB News
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
